Chugai expects full-year results above forecast on drug exports and royalties
FROM THE WIRE · FINANCE.YAHOO.COM
Investing.com -- Chugai Pharmaceutical (TYO:4519) on Tuesday said it expects full-year results to exceed its forecast after stronger overseas drug sales and growth in its domestic product portfolio lifted revenue and profit during the first nine months of 2026. Still guessing…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishBetter-than-expected guidance from a large Japanese drugmaker can support the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Core revenue for the first nine months rose 17.2% to ¥1.068 trillion.
- 02Core operating profit increased 19% to ¥536.1 billion.
- 03Royalties from Hemlibra and NEMLUVIO supported other revenue.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets